| Literature DB >> 28751837 |
Nadia Aspromonte1, Michele Massimo Gulizia2, Andrea Di Lenarda3, Andrea Mortara4, Ilaria Battistoni5, Renata De Maria6, Michele Gabriele7, Massimo Iacoviello8, Alessandro Navazio9, Daniela Pini10, Giuseppe Di Tano11, Marco Marini5, Renato Pietro Ricci1, Gianfranco Alunni12, Donatella Radini3, Marco Metra13, Francesco Romeo14.
Abstract
Changing demographics and an increasing burden of multiple chronic comorbidities in Western countries dictate refocusing of heart failure (HF) services from acute in-hospital care to better support the long inter-critical out-of- hospital phases of HF. In Italy, as well as in other countries, needs of the HF population are not adequately addressed by current HF outpatient services, as documented by differences in age, gender, comorbidities and recommended therapies between patients discharged for acute hospitalized HF and those followed-up at HF clinics. The Italian Working Group on Heart Failure has drafted a guidance document for the organisation of a national HF care network. Aims of the document are to describe tasks and requirements of the different health system points of contact for HF patients, and to define how diagnosis, management and care processes should be documented and shared among health-care professionals. The document classifies HF outpatient clinics in three groups: (i) community HF clinics, devoted to management of stable patients in strict liaison with primary care, periodic re-evaluation of emerging clinical needs and prompt treatment of impending destabilizations, (ii) hospital HF clinics, that target both new onset and chronic HF patients for diagnostic assessment, treatment planning and early post-discharge follow-up. They act as main referral for general internal medicine units and community clinics, and (iii) advanced HF clinics, directed at patients with severe disease or persistent clinical instability, candidates to advanced treatment options such as heart transplant or mechanical circulatory support. Those different types of HF clinics are integrated in a dedicated network for management of HF patients on a regional basis, according to geographic features. By sharing predefined protocols and communication systems, these HF networks integrate multi-professional providers to ensure continuity of care and patient empowerment. In conclusion, This guidance document details roles and interactions of cardiology specialists, so as to best exploit the added value of their input in the care of HF patients and is intended to promote a more efficient and effective organization of HF services.Entities:
Keywords: Chronic care model; Clinical competence; Disease networks; Heart failure; Outpatient clinics
Year: 2017 PMID: 28751837 PMCID: PMC5520754 DOI: 10.1093/eurheartj/sux009
Source DB: PubMed Journal: Eur Heart J Suppl ISSN: 1520-765X Impact factor: 1.803
Characteristics of patients with acute HF hospitalized in cardiology or medicine wards and CHF patients followed-up in outpatient clinics
| Acute HF | Chronic HF | ||
|---|---|---|---|
| INHF outcome ( | CONFINE | INHF outcome ( | |
| Age years | 72 ± 12 | 79 ± 10 | 69 ± 12 |
| Proportion female | 40% | 52% | 24% |
| Body mass index | 28 ± 5 | 27 ± 5 | 27 ± 4 |
| Obesity (BMI > 30 kg/m2) | 29% | 22% | 22% |
| Hypertension | 58% | 63% | 43% |
| Chronic kidney dysfunction | 32% | 44% | 21% |
| COPD | 30% | 27% | 21% |
| Diabetes | 40% | 32% | 30% |
| Anaemia | 39% | 40% | 20I |
| Ischaemic aetiology | 42% | 44% | 46% |
| Atrial fibrillation | 8% | 43% | 30% |
| LV ejection fraction% | 38 ± 14 | 43 ± 12 | 38 ± 11 |
| Pressione sistolica mmHg | 134 ± 33 | 141 ± 27 | 126 ± 19 |
| Sodium < 136 mEq/l | 19% | 28% | 9% |
| Creatinine mg/dl | 1.2 [1.0–1.6] | 1.5 ± 0.9 | 1.2 [1.0–1.5] |
| In-hospital mortality | 6.4% | 4.4% | 5.9% |
| Length of stay | 12 ± 10 | 14 ± 10 | — |
| Beta blockers | 65% | 31% | 79% |
| ACE inhibitors/ARB | 78% | 79% | 90% |
| Aldosterone antagonists | 59% | 32% | 38% |
ACE, angiotensin converting enzyme; ADHF, acute decompensated heart failure; ARB, angiotensin receptor blockers; BMI, body mass index; COPD, chronic obstructive pulmonary disease; HF, heart failure; INHF, Italian Network on Heart Failure; LV, left ventricular.
aMedicine wards.
bOne-year post-discharge.
Figure 1Care referral pathways within the HF network based on patients’ clinical profiles. Stable patients at low-to-moderate risk of cardiovascular events, as well as frail elderly subjects with multiple comorbidities, should be managed in the community (green circle), with a focus on clinical monitoring and patient education. Patients with acute exacerbations or de novo gradual—onset symptoms should be referred to the geographically nearest (proximity) cardiology using shared protocols based on validated biomarkers. Proximity cardiology units (yellow circles) should admit to hospital patients with acute HF syndromes or outpatients from the community to perform appropriate diagnostic tests, to start or optimize drug therapy and to draft a tailored follow-up plan. Proximity cardiology units should share with network hubs the follow-up care of patients with advanced HF who are candidates to or have received heart transplantation or mechanical circulatory support. Network hubs, based on geographic location, are tertiary referral cardiology units (red circles) that should offer advanced treatment options to unstable patients at high risk of events. All network nodes should entertain close relationships with palliative network nodes for shared care of end-stage HF patients. CRT, cardiac resynchronization therapy; HF, heart failure; HTx, heart transplantation; ICD, implantable cardioverter defibrillator; LVAD, left ventricular assist device; Tx, transplantation.
Recommended activities of HF outpatient clinics
| Activity domains | Key procedures |
|---|---|
| Functional evaluation | Assess NYHA class at each visit Perform 6-min walking test at baseline and according to clinical course Perform cardiopulmonary test in advanced HF patients and heart transplant candidates |
| Quality of life | Assess using validated questionnaires eneric (e.g. SF36, euroQOL). pecific (e.g. Minnesota Living with Heart Failure, Kansas City Cardiomyopathy) |
| Revision and optimization of medical therapy | Prepare a standardized scheme of instructions for all prescribed drugs (indications, common side effects, drug interactions) Register in the clinical record any therapeutic changes and confirm the patient has been properly instructed Check all medicines taken by the patient, including OTC drugs and supplements Check drug intolerances/allergies in order to reassess any stopped or uninitiated treatment Verify adherence to prescribed treatment and investigate causes of poor compliance Establish a procedure to systematically identify eligible patients who do not receive appropriate medications. |
| Revision and optimization of therapy with devices | Establish a procedure to adequately identify patients eligible for device therapy (exclusion of reversible causes of heart failure, appropriate drug titration, careful evaluation of estimated life expectancy) Communication with electrophysiologists for conflicting indications Training in device management in order to detect device malfunction or need for reprogramming; Documentation in the medical record of any variation in device parameters Discussion with the patients of the benefit/risk of electrical therapies |
| Nutritional evaluation | Restriction of sodium and fluid intake to decrease fluid retention and minimize diuretic dose Cooperation with a dietician Sequential recording of weight and body mass index Personalized dietary guidelines according to co-morbidity (e.g. diabetes, obesity, dyslipidaemia, renal failure) Prevention of cardiac cachexia caused by reduced synthesis and/or absorption of nutrients for liver and intestinal congestion |
| Follow-up schedule | Guarantee scheduled or urgent visits Assure early follow-up after discharge from an ADHF admission. Contact high-risk patients within 72 h after discharge from an ADHF admission. Schedule follow-up visits according to needs Plan close follow-up, till proper education of the patient and family and clinical stability have been achieved Schedule monitoring of biochemical or instrumental parameters according to therapy and clinical course |
| Communication | Set up an open and sensitive communication system to allow patients to express their needs and desires Explain potential complications related to the course of the disease and the available treatment options. Investigate potential defects in patient understanding of their clinical status Take into account the discrepancies between individual life expectancy and the estimates of validated scores |
| Advance directives | Investigate the perceptions of patients and family members about disease progression and the choices to be made in the most advanced stages Indicate in the clinical record patient’s wishes with respect to cardiopulmonary resuscitation, the possible deactivation of the defibrillator, invasive or surgical procedures, hospitalization Record options in the plan of care and advance directives |
| Continuous staff training | Specific training for nurses (elements of pathophysiology, pharmacology, self-management approach to care, psychosocial issues, quality of life, and palliative care) Specific training for outpatient clinics taking care patients with advanced HF and candidates to heart replacement therapy Promotion of clinical audit |
| Quality assessment | Equipment and personnel adequate for appropriate patient management Implementation of a continuous monitoring system of indicators within the HF outpatient clinic network Electronic sharing of medical records to facilitate audit procedures |
ADHF, acute decompensated heart failure; HF, heart failure; NYHA, New York Heart Association; OTC, over the counter.
Clinical competencies of medical staff in HFOCs
| (A) Community-based HFOCs |
| Knowledge of:
the pathophysiology, differential diagnosis, stages, and natural history of HF the typical history and physical examination findings, and their limitations, in the evaluation of HF syndromes the indications, contraindications, and clinical pharmacology of drugs used for HF treatment, including adverse effects the appropriate pharmacological or non-pharmacological treatment for the prevention of HF in patients with either presymptomatic (stage B) or overt (stage C) HF the effects and interactions of HF with other organ systems (kidney, nutritional, metabolic) and in the setting of other systemic disease the management of cardiac arrhythmias in HF patients, as well as the indications and risks of ICD, CRT and arrhythmia ablation to evaluate and manage patients with new-onset and chronic HF to use history and physical examination findings to accurately assess volume status and perfusion in HF patients to recognize and manage comorbidities in HF patients to recognize, manage, and seek appropriate consultation for depression or undue anxiety in HF patients as part of their overall care to interpret imaging results in the evaluation of HF patients to identify appropriate candidates for palliative care and hospice Identify and address financial, cultural, and social barriers to diagnostic and treatment recommendations Utilize an interdisciplinary, coordinated, team approach for patient management, including care transitions and palliative care Utilize appropriate care settings and teams for various levels and stages of HF Incorporate risk/benefit analysis and cost considerations in diagnostic and treatment decisions Effective management of end-of-life issues, including family meetings across the spectrum of patients with HF Communicate with and educate patients and families across a broad range of cultural, ethnic, and socioeconomic backgrounds Engage in shared-decision making with patients, including options for diagnosis and treatment |
| (B) Hospital-based HFOCs. In addition to (A) |
| Skills:
to evaluate and manage patients with new-onset, chronic, and acute decompensated HF to appropriately obtain and incorporate data from the history, laboratory studies, and imaging modalities in evaluation and management of HF patients to select and implement appropriate arrhythmia management, including utilization of ICD, CRT, and ablation of arrhythmias in patients with HFof all aetiologies and severity to manage HF patients with complex contributing comorbidities to manage refractory HF with temporary MCS use of invasive and non-invasive methods of mechanical ventilation use of continuous renal replacement therapy (SCUF/CVVH/CVVHD/CVVHDF) Effectively utilize an interdisciplinary approach to monitor HF outpatients to maintain stability and avoid preventable hospitalization |
| (C) Advanced care HFOCs and HRT programs. In addition to (B) |
| Knowledge of:
the management and diagnostic strategies for populations with HF not due to ischaemic heart disease, including infiltrative and restrictive cardiomyopathies, inherited cardiomyopathies, and those associated with pregnancy and chemotherapy the management strategies for highly specialized populations with HF, including those associated with congenital heart disease and chronic pulmonary disease the indications, contraindications, and clinical pharmacology for intravenous, vasoactive, and inotropic drugs used for cardiovascular support in advanced/refractory HF the indications for referral for HRT the types of and indications for MCS the indications and clinical rationale for the pharmacological management of patients implanted with MCS the clinical pharmacology and use of immunosuppressive medications and other interventions in heart transplant patients in the treatment of acute rejection to evaluate and manage patients with severe HF despite treatment to perform invasive haemodynamic monitoring to incorporate results of haemodynamic measurements and monitoring to make appropriate management decisions in complex or advanced HF patients of all aetiologies and severity or in patients with MCS to interpret and incorporate results of cardiopulmonary exercise testing into management of HF patients, including physical activity and exercise recommendations to manage patients with advanced HF and complex arrhythmias, including patients with MCS, in conjunction with clinical cardiac electrophysiologists to appropriately utilize initial screening studies to determine patient eligibility for HRT of individuals cared for at non-transplant/non-ventricular assist device facilities, in collaboration with individuals working in HRT programs to evaluate, order all appropriate testing, and determine the appropriateness of a patient for cardiac transplant or MCS to evaluate and manage heart transplant/MCS recipients to identify and manage patients who require transition from hospital to home or to a care facility while on infusion of inotropic or vasoactive agents to identify and manage patients who require transition from hospital to home or to a care facility after heart transplant or permanent MCS Identify the financial, social, and emotional barriers to successful outcomes after surgery Clearly and objectively discuss the therapies available for advanced HF, including palliative care, transplant, or MCS Effectively lead and communicate with the interdisciplinary team involved in heart transplant and MCS |
Based on the ACC 2015 Core Cardiovascular Training Statement (COCATS 4).
CRT, cardiac resynchronization therapy; HF, heart failure; HFOCs, heart failure outpatient clinics; HRT, heart replacement therapy; ICD, implantable cardioverter defibrillator; MSD, mechanical circulatory support; SCUF, slow continuous ultrafiltration.
Structure and organization of HFOCs
| Clinic | (A) Community based | (B) Hospital based | (C) Advanced care and HRT |
|---|---|---|---|
| Location | Community:
Primary care territorial unit, health home, functional territorial aggregation, primary care association General cardiology outpatients’ clinic Non-cardiology units (internal medicine, geriatrics, emergency medicine) Hospitals with emergency services only Intermediate long-term care units Cardiac rehabilitation units | Hospitals with cardiology units:
Cardiology inpatient unit CICU Cardiac catheterization laboratory either on site or in a functionally linked centre EP Laboratory either on site or in a functionally linked centre | Hospitals with a cardiology division:
cardiology inpatient unit CICU on site cardiac catheterization laboratory open 24 h/day, 7 days/week, with expertise in performing EBM on site EP Laboratory cardiac surgery unit Integrated Cardiac-Surgical HF program |
| Patient profile | Patients with stable chronic HF have concluded the risk stratification process OR do not need additional diagnostic/therapeutic procedures or these are ongoing in collaboration with hospital-based clinics | Patients with newly diagnosed HF who need
risk stratification investigation of the aetiology of HF Patients with recent decompensation Patients needing interventional diagnostic or therapeutic procedures | Patients at high risk of decompensation (severe exercise intolerance and/or severe cardiac dysfunction) Patients who are taken care of in (B), but need diagnostic and/or therapeutic procedures only available in (C). Patients needing cardiac surgery Patients with advanced HFc patients with advanced HF who are potential candidates for HRT heart transplant/MCSD recipients |
| Requirements | Compliance with regional accreditation standards for outpatient clinics | Compliance with regional accreditation standards for outpatient Outpatient clinic dedicated to HF patients Day-hospital and/or Day-service and/or intensive hospital-based outpatient care Either on site or functionally linked EP laboratory with expertise in both ablation and pacing, including cardiac resynchronization therapy Either on site or functionally linked cardiac catheterization laboratory | In addition to (B):
multidisciplinary team led by HF cardiologists, cardiac surgeons and HF specialist nurses, and including additional health-care professionals as needed the multidisciplinary team is responsible for integration across the HF care continuum compliance with current legislation about heart transplant and MCSD centres active MCSD program (heart transplant programs) on site availability of the facilities and competencies necessary for the diagnosis and treatment of the potential complications of HRT |
| Equipment and facilities | Sphygmomanometer Electrocardiograph Pulse oximeter Scales Defibrillator Cardiac ultrasound scanner | In addition to (A):
cardiac ultrasound scanner defibrillator dressing and phlebotomy tray Holter monitoring cardiopulmonary exercise testing advanced cardiac imaging equipment for the interrogation of implantable devices remote device monitoring program | As in (B) but all the facilities and equipment must be available on site, and in addition:
telemetry equipment, allowing also oxygen saturation monitoring by pulse oximeter and non-invasive blood pressure monitoring nuclear cardiology equipment for MCSD monitoring |
| Minimal volume of activity | Time slots and/or days dedicated to HF patients | At least 2 days/week dedicated to HF patients Fast track (within 72 h) for unstable patients Nurse-led telephone follow-up for unstable patients | In addition to (B):
at least 3 days/week dedicated to HF patients telephone consulting 24 h/day, 7 days/week specialist assistance for emergencies in the hospital 24 h/day, 7 days/week |
| Staff | At least one physician with expertise in HF At least one nurse | At least one HF cardiologist At least one HF specialist nurse responsible for care integration across the HF spectrum The involvement, in a multidisciplinary team, of additional medical (internists, geriatricians, nephrologists, etc.) and non-medical (psychologists, nutritionists, dietitians, physiotherapists) professionals is desirable | At least three HF cardiologists HF specialist nurses Cardiac surgeons with expertise in the surgical treatment of HF Multidisciplinary team nurses and cardiac surgeons with expertise in the management of MCSD recipientsd; this is desirable for all Advanced care clinics, so that they can participate in the follow-up of MCSD recipients nurses with expertise in the management of heart transplant recipients |
| Services | Referral of patients newly diagnosed with HF to hospital clinics, if the aetiology is unclear Implementation of guideline-directed medical therapy, assessment of clinical stability and referral to hospital-based clinics where appropriate Support to institutions or home care services for frail patients Integration with palliative care services | In addition to (A):
timely consultation for confirmation of HF diagnosis, risk stratification, implementation of guideline-directed therapy, referral to advanced care clinics/HRT programs when appropriate referral of stable patients at low-risk of events to community-based clinics, according to predefined protocols support to institutions/home-care services for frail/end-stage patients by means of telemonitoring development of collaborative clinical pathways with the ER, and internal medicine and cardiology units, that describe appropriateness criteria for admission to the CICU, transfer to a regular floor/intermediate care unit, referral to palliative care services, admission of low-risk patients to the ER observation unit with subsequent follow-up in the HF clinic patient self-care education, including the preparation of educational material for patients and care givers continuous education of health-care professional working in the hospital and in the community | In addition to (B):
referral of stable patients at low risk for hospitalization to Community-based clinics, according to defined protocols referral of potential candidates for HRT to HRT programs follow-up of MCSD recipients assessment of patient eligibility for heart transplant or MCSD management of patients on the transplant waiting list and of transplant recipients continuous education of MCSD recipients and community health-care professional involved in the care of these patients evaluation of the quality of life before and after MCSD implant by means of validated questionnaires |
CICU, cardiac intensive care unit; CVVH, continuous vene-venous hemofiltration; CVVHD, continuous vene-venous hemodialysis; CVVHDF, continuous vene-venous hemodiafiltration; EP, electrophysiology; HF, heart failure; HRT, heart replacement therapy; EBM, endomyocardial biopsy; MCSD, mechanical circulatory support devices.
aHRT: heart transplant, implant of durable mechanical circulatory support devices.
bStable chronic HF is defined as:
• stable symptoms on oral therapy for at least 15 days;
• stable dose of diuretics for at least 15 days;
• no signs of congestion (peripheral oedema, rales, jugular veins distension);
• no symptomatic hypotension.
cIn accordance with the 2007 position statement from the Heart Failure Association of the European Society of Cardiology, Advanced HF is defined as:
• NYHA functional class III-IV symptoms;
• episodes of fluid retention and/or of reduced cardiac output at rest;
• objective evidence of severe cardiac dysfunction;
• severe impairment of functional capacity;
• history of ≥ 1 HF hospitalisation in the past 6 months;
• presence of all the previous features despite attempts to optimize therapy, including CRT, when indicated.
dSee Table for detailed staff competencies required.